From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia - Top-Institutions - MDSpire

From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia

  • By

  • Milad Rasouli

  • Marie Dalem

  • Marc H.G.P. Raaijmakers

  • Peter D. Katsikis

  • Stefan J. Erkeland

  • June 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    University of Minnesota
    University of Minnesota

    Minneapolis, Minnesota

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    City of Hope
    City of Hope

    Duarte, California

    Key Differentiators

    • Hematology
    • Oncology

  • #5

    Fred Hutchinson Cancer Research Center
    Fred Hutchinson Cancer Research Center

    Seattle, Washington

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia

  • by Milad Rasouli, Marie Dalem, Marc H.G.P. Raaijmakers, Peter D. Katsikis, Stefan J. Erkeland

  • June 1, 2026

Related Content

Clinical heterogeneity and treatment optimization in anti-KLHL11 encephalitis: two case reports and literature review

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026